Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

To explore the impact of targeted therapy for breast cancer suggested by proteomic and
genomic profiling using RPMA, targeted resequencing, IHC analysis, WGS, RNA-seq, and Exome
sequencing on progression-free survival. When a molecular target cannot be identified, the
patient will be treated with a therapy selected on an empirical basis by the
investigator/treating physician at the individual site and will be followed for survival
status. Only available, FDA-approved agents will be used.

Inclusion Criteria:

- Life expectancy of >3 months

- Diagnosis of metastatic breast cancer or an advanced gynecological malignancy with
measurable disease

- Age greater than or equal to 18 years

- ECOG performance status of 0-1

- Able to undergo two biopsies to obtain tissue with first biopsy required and second
biopsy optional

- Have failed or unable to tolerate previous treatment regimen

- Adequate organ and bone marrow function as defined by ANC ≥ 1.5 x 109/L; Hgb 9 g/dL;
platelets greater than 100 x 109/L; creatinine ≤ 1.5 mg/dL; bilirubin ≤ 2.5 x ULN; AST
and ALT ≤ 2.5 x ULN (or ≤ 5 x ULN if due to underlying liver metastases); INR ≤ 1.5 x
ULN (except in the case of anticoagulation therapy)

Exclusion Criteria:

- Metastatic lesions that are not accessible to biopsy

- Symptomatic CNS metastasis

- Previous history of another malignancy within 5 years of study entry

- Uncontrolled concurrent illness

- Known HIV, HBB, and/or HCV infection

- Pregnant or breast feeding or childbearing potential and not using adequate birth
control